Belrose Pharma focuses on rare diseases and uses its proprietary “releasable linker” conjugation technology and other techniques to improve the clinical efficacy of both novel therapeutics and ...
OPKO-CURNA is developing a unique therapeutic modality focusing on the targeted up-regulation of protein levels via the targeted up-regulation of gene expression.
Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technologies. Their integrated platform enables the discovery, design and development of ...
Protein Genomics carries out research and development on sophisticated, high performance biopolymers for potential applications in the wound healing, tissue regeneration, dermal filler and ...
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is ...
